.svg)
This summary draws from an exclusive The Jakarta Post feature. The full article is available to The Jakarta Post subscribers here.
Malaria continues to pose a serious public health threat in Indonesia. Despite notable progress where approximately 70% of the country’s regencies and cities have been declared malaria-free, the disease remains entrenched in areas such as the Papua region.
Part of Indonesia's ongoing efforts to curb malaria include advancing malaria vaccine research. The country's National Research and Innovation Agency (BRIN), together with researchers from the Eijkman Research Center for Molecular Biology, the Eijkman-Oxford Clinical Research Unit (EOCRU) and the University of Indonesia’s School of Medicine (FKUI), has initiated the Phase 2 clinical trials of the PfSPZ Vaccine developed by Sanaria Inc. Over 340 Indonesian Army soldiers have received the three-dose regimen, following which a scheduled deployment to Papua is expected.
The clinical trial aims to assess the vaccine’s ability to prevent malaria infection among populations most at risk. While existing tools and interventions remain effective, the COVID-19 pandemic has reinforced the importance of vaccines in preventing severe illness and death. Despite the global disruption to health systems brought about by the pandemic, progress toward elimination must be safeguarded. Innovation, alongside proven interventions, is essential to secure a malaria-free future and protect communities most at risk.
